MARKET

RAPP

RAPP

Rapport Therapeutics Inc
NASDAQ
41.75
-0.30
-0.71%
After Hours: 41.79 +0.04 +0.10% 18:37 07/10 EDT
OPEN
42.06
PREV CLOSE
42.05
HIGH
42.06
LOW
38.88
VOLUME
435.60K
TURNOVER
--
52 WEEK HIGH
43.76
52 WEEK LOW
11.71
MARKET CAP
2.00B
P/E (TTM)
-16.0472
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RAPP last week (0629-0703)?
Weekly Report · 6d ago
Rapport Therapeutics CEO Abraham Ceesay disposes of common shares worth $327,031.55
PUBT · 07/01 20:05
Weekly Report: what happened at RAPP last week (0622-0626)?
Weekly Report · 06/29 09:46
Rapport Therapeutics Initiated at Outperform by Leerink Partners
Dow Jones · 06/24 18:51
Rapport Therapeutics Price Target Announced at $52.00/Share by Leerink Partners
Dow Jones · 06/24 18:51
Rapport Therapeutics initiated with an Outperform at Leerink
TipRanks · 06/24 10:35
RAPPORT THERAPEUTICS INC <RAPP.O>: LEERINK PARTNERS INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $52
Reuters · 06/24 10:07
Weekly Report: what happened at RAPP last week (0615-0619)?
Weekly Report · 06/22 09:52
More
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.

Webull offers Rapport Therapeutics Inc stock information, including NASDAQ: RAPP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RAPP stock methods without spending real money on the virtual paper trading platform.